Stockreport

BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

BiondVax Pharmaceuticals Ltd. - American Depositary Shares  (BVXV) 
US:NASDAQ Investor Relations: biondvax.com/investors
PDF JERUSALEM, Oct. 22, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase 3 Universal Influenza Vaccine candidate, ann [Read more]